Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...
Immunome (IMNM) announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC. Discover ...
IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial ...
The existing data underscore its broad potential in both lymphomas and solid tumors. Notably, a ROR1 ADC combined with R-CHP has demonstrated an impressive complete response (CR) rate in a Phase II ...
6. Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner Radiance Biopharma is paying $15 million upfront for rights to a ROR1-directed antibody-drug conjugate from a ...
Plus, news about Harmony Biosciences and Reverb Therapeutics: Genuine Biotech files for HKEX listing: The drug developer, which has multiple locations in China, ...
BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the treatment of ROR1-positive hematological malignancies and solid tumors. ROR1 is a transmembrane receptor ...
BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the treatment of ROR1-positive hematological malignancies and solid tumors. ROR1 is a transmembrane receptor ...
WNT proteins are secreted symmetry breaking signals that interact with cell surface receptors of the FZD family to regulate a multitude of developmental processes. Studying selectivity between WNTs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback